


- 1. An antibody to the human IL-12 p75 heterodimer which consists of a p35 subunit and a p40 subunit wherein said antibody
- (a) immunologically reactive with an epitope presented by the p75 heterodimer of human IL-12, but is not immunologically reactive with any epitope presented by said p40 subunit; and
- (b) is produced from a mouse which is deficient in the gene encoding said p35 subunit or the p40 subunit of III-12.
- 2. The antibody of claim, wherein the antibody is a monoclonal antibody.
- 3. The antibody of claim \, wherein the antibody is produced from a cell line of the mouse.
- 4. The antibody of claim 1, wherein the antibody cross reacts with rhesus monkey IL-12.
- 5. The antibody of claim 1, wherein the antibody is humanized.
- The antibody of claim 2, wherein the antibody is produced by a hybridoma having ATCC designation number HB-12446, or a humanised watibody, thereof.
 - The antibody of claim 2, wherein the antibody is humanized.



- 14. A monoclonal antibody to human IL-12 which consists of a p35 subunit and a p40 subunit forming a p75 heterodimer, wherein said monoclonal antibody
- (a) immunologically reacts with an epitope presented by the p75 heterodimer of human IL-12, but is not immunologically reactive with any epitope presented by said p40 subunit; and
 - (b) neutralizes at least about 90% of the bioactivity of human IL-12.

₫ ₫ 15

2þ

4


15. The antibody of claim 14, wherein the antibody neutralizes at least about 90% bioactivity of human IL-12 by inhibiting IL-12 stimulated PHA-activated human lymphoblast proliferation wherein

- 16. The antibody of claim 14, wherein the antibody neutralizes at least about 90% bioactivity of human IL-12 by inhibiting IL-12 stimulated IFN-γ production wherein the concentration of the antibody is 0.5 μg/ml and the concentration of said human IL-12 is 0.25 ng/ml.
- 17. The antibody of claim 14, wherein the antibody cross reacts with rhesus monkey IL-12.
- 18. The antibody of claim 14, wherein the antibody is humanized.
- 19. The antibody of claim 14, wherein the antibody is produced by a hybridoma.
- 20. The antibody of claim 19, wherein the antibody is humanized.
- 21. The antibody of claim 14, wherein the antibody is produced by a hybridoma having ATCC designation number HB-12446/, or a humanized antibody. Hereof.
- The antibody of claim 21, wherein the antibody is humanized.
- 23. The antibody of claim 14, wherein the antibody is produced by a hybridoma having ATCC designation number HB-12447/100 a humanized antibody, Thereof.

B

20

B



The hybridoma of claim 29 wherein the hybridoma is HIL-12F3-16F2 having ATCC designation number HB-12447.

The hybridoma of claim 29, wherein the hybridoma is HIL-12F3-20E11 having ATCC designation number HB-12448.

38. The hybridoma of claim 39, wherein the hybridoma is HIL-12F3-16G2 having ATCC designation number HB-12449.

- 34. A method for producing an antibody that selectively immunologically reacts with the human IL-12 p75 heterodimer which consists of a p35 subunit and a p40 subunit, comprising the steps of:
- (a) immunizing a mammal deficient in a gene encoding said p35 subunit or said p40 subunit with the human IL-12 p75 heterodimer to produce antibodies;
 - (b) obtaining antibodies from the immunized mammal;
 - (c) screening said antibodies for their ability to selectively bind an epitope presented by the p75 heterodimer to obtain said selectively binding antibody.
 - A method for producing a monoclonal antibody that selectively immunologically reacts with the human IL-12 p75 heterodimer which consists of a p35 subunit and a p40 subunit, comprising the steps of:
 - (a) immunizing a mammal deficient in a gene encoding said p35 subunit or said p40 subunit with the human IL-12 p75 heterodimer to produce antibodies;
 - (b) harvesting antibody producing cells from the immunized mammal;

- (c) forming a monoclonal antibody producing hybridoma from said cells and obtaining said monoclonal antibody;
- (d) screening said moncloral antibody produced by said hybridoma for the ability to selectively bind to an epitope presented by the p75 heterodimer to obtain said selectively binding monoclonal antibody.
- 36. The method of claim 35, wherein the antibodies produced from the hybridoma are further screened and selected for their ability to cross react with rhesus monkey IL-12.